[{"text": "AmMax Bio Announces First Patient Dosed in Phase 2a Study Evaluating AMB-066 in Patients with Colorectal Cancer Minimal Residual Disease AmMax Bio, Inc. Mon, Jan 27, 2025, 4:00 PM 2 min read AmMax Bio, Inc. AMB-066 is a potential first-in-class treatment for CRC MRD ~20,000 patients diagnosed annually in U.S.; no currently approved therapies REDWOOD CITY, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (\u201cAmMax\u201d), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, today announced the dosing of the first patient in its Phase 2a study ( NCT06617858 ) evaluating AMB-066 for the treatment of patients with colorectal cancer minimal residual disease (CRC MRD). This study is being conducted at The University of Texas MD Anderson Cancer Center and led by Van K. Morris, M.D., Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine. \u201cDosing the first patient in this trial marks a significant milestone in our efforts to address critical unmet needs in oncology,\u201d said Larry Hsu, Ph.D., Chairman and Chief Executive Officer of AmMax. \u201cAMB-066 represents a promising first-in-class therapeutic candidate for CRC MRD, and AmMax is committed to advancing its development. We look forward to sharing further updates as the study progresses.\u201d CRC MRD is diagnosed when a patient without radiographic evidence of tumor tests positive with circulating tumor DNA. In the U.S., an estimated 20,000 patients annually are diagnosed with CRC MRD following definitive therapy, which includes curative intent surgery with or without perioperative chemotherapy. There are no therapies currently approved in the U.S. for CRC MRD; the standard of care is limited to clinical observation. \u201cPatients with CRC MRD face a significantly higher risk of developing recurrence and metastasis and urgently need effective treatment options. The potential utility of AMB-066 for treating CRC MRD is supported by compelling preclinical data as well as a large clinical safety database of approximately 200 individuals,\u201d said Dorothy Nguyen, M.D., Head of Clinical Development at AmMax. \u201cWe are excited about the Phase 2a study and look forward to advancing this important trial.\u201d About AMB-066 AMB-066 is a potent monoclonal antibody targeting the colony stimulating factor 1 receptor (CSF1R) currently being evaluated in the clinic for the treatment of patients with CRC MRD ( https://bit.ly/AMB-066 ). The antibody has been tested in approximately 200 patients and healthy volunteers across six clinical trials for other indications and has been found to be generally safe and well tolerated. About AmMax Bio Inc. \u200bAmMax, founded by Larry Hsu, Ph.D., in 2020, is a clinical-stage biotechnology company focused on the development of innovative therapeutics for cancer patients. AmMax has built a robust oncology pipeline addressing significant unmet needs and large commercial opportunities. The Company\u2019s pipeline includes primarily AMB-066 for CRC MRD, AMB-104, a novel antibody-drug conjugate for acute myeloid leukemia (AML), and AMB-051, an intra-articular injection for tenosynovial giant cell tumor (TGCT). For more information, please visit the company\u2019s website at www.AmMaxBio.com . Story Continues Contact For corporate development: For investor inquiry: Laura Zhu, Ph.D., MBA Andrew Sauter CBO CFO laurazhu@ammaxbio.com andrewsauter@ammaxbio.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRC", "date": "2025-01-27T13:00:00+00:00", "sentiment": {"score": 0.25435561034828424, "confidence": 0.264777272939682, "probabilities": {"positive": 0.264777272939682, "negative": 0.010421662591397762, "neutral": 0.7248010635375977}}, "embedding": [-0.052445996552705765, -0.0661773830652237, -0.0005017130170017481, -0.03583147004246712, -0.07032446563243866, -0.12895163893699646, -0.17547696828842163, 0.2450505495071411, 0.0628790631890297, -0.006796304136514664, -0.11417653411626816, 0.10320077836513519, 0.00553403003141284, 0.051744960248470306, -0.22410739958286285, 0.10769271850585938, 0.12805356085300446, -0.04495781287550926, -0.12225989252328873, 0.07518446445465088, -0.0874619409441948, -0.03683725371956825, 0.08749429136514664, 0.1413186490535736, -0.11886723339557648, -0.11672607064247131, -0.03791235387325287, 0.021739846095442772, -0.049767762422561646, -0.044256024062633514, 0.14904829859733582, 0.19159002602100372, 0.06602591276168823, 0.07076629996299744, 0.02196279540657997, 0.0380360409617424, 0.010800731368362904, 0.06686842441558838, -0.10522771626710892, -0.018442021682858467, -0.06305182725191116, -0.027694080024957657, -0.012788036838173866, 0.1469591110944748, 0.09210731089115143, -0.23590973019599915, -0.06317166984081268, -0.12894518673419952, 0.059569112956523895, 0.18941092491149902, -0.019433576613664627, 0.049664825201034546, -0.16992592811584473, 0.22482430934906006, 0.07879354059696198, 0.011287670582532883, -0.1394474059343338, -0.03592904284596443, 0.09385834634304047, 0.056489743292331696, -0.05912116914987564, -0.16229654848575592, 0.04358726739883423, -0.007006925530731678, 0.2275163233280182, -0.014600281603634357, -0.01273783016949892, -0.10946682095527649, -0.08217841386795044, -0.007456820458173752, 0.005715668201446533, -0.02408229187130928, 0.032764311879873276, 0.07520369440317154, -0.0806025043129921, 0.005268719047307968, 0.09454213082790375, 0.0954212099313736, 0.01701788604259491, 0.008115692064166069, -0.03223320096731186, -0.02543618157505989, 0.0736265778541565, -0.16109314560890198, -0.030497854575514793, -0.001249037915840745, -0.06202002614736557, 0.19095176458358765, -0.0038855206221342087, 0.07595310360193253, 0.06450191140174866, 0.05374196171760559, -0.030495647341012955, -0.013309374451637268, 0.019335323944687843, -0.016771595925092697, -0.073396697640419, -0.05400758981704712, 0.07661475241184235, -0.01748778484761715, -0.028886117041110992, 0.03288061544299126, -0.11272890865802765, -0.03703848272562027, 0.0274000633507967, -0.15096637606620789, 0.013728516176342964, 0.030721014365553856, -0.025828219950199127, 0.0034073726274073124, 0.1078542172908783, 0.03418905287981033, 0.16604386270046234, -0.05549302697181702, 0.07631642371416092, 0.18508696556091309, -0.04956282675266266, 0.015360173769295216, 0.14572793245315552, 0.022514542564749718, -0.01789902336895466, -0.038599893450737, 0.026969898492097855, -0.11468497663736343, 0.1035279631614685, 0.13074783980846405, 0.025458917021751404, 1.0744349708985846e-32, 0.05894972383975983, -0.008377064019441605, 0.09116559475660324, 0.05991432070732117, -0.10805575549602509, 0.03843529522418976, 0.027013670653104782, -0.09288077056407928, -0.08755506575107574, -0.19385510683059692, 0.07114621996879578, 0.06116979196667671, 0.042562562972307205, 0.03884380683302879, -0.1370309442281723, -0.10271822661161423, 0.050015900284051895, 0.04002750664949417, -0.19008424878120422, -0.041875142604112625, -0.004451551474630833, 0.08324367552995682, 0.048690952360630035, -0.19066986441612244, -0.014823338016867638, 0.10939376056194305, -0.11504962295293808, 0.20438358187675476, 0.06460122019052505, 0.0423152782022953, -0.13817504048347473, 0.08757922053337097, 0.017221609130501747, 0.04608658328652382, -0.14887180924415588, -0.012563005089759827, -0.1349964141845703, -0.056383490562438965, 0.07850009202957153, 0.10162223875522614, -0.06750036776065826, 0.0557987317442894, -0.06799867749214172, -0.08095257729291916, 0.018678657710552216, -0.25380244851112366, 0.024562865495681763, 0.004641598090529442, -0.05274498835206032, -0.06400120258331299, -0.07547731697559357, -0.09493641555309296, -0.04105709493160248, -0.1117485761642456, -0.11782585829496384, -0.046667471528053284, -0.11500345170497894, 0.011629404500126839, 0.11514852941036224, 0.22438867390155792, 0.02187696285545826, 0.04865804687142372, -0.1113709881901741, 0.2030181586742401, -0.010468225926160812, 0.08193899691104889, -0.14323505759239197, -0.026164894923567772, 0.05880066752433777, 0.11369940638542175, -0.019768008962273598, -0.0441969558596611, 0.2901017665863037, 0.012849302962422371, 0.20277813076972961, -0.09022528678178787, 0.23867952823638916, 0.05967053771018982, -0.06378376483917236, 0.04918324947357178, -0.07415981590747833, 0.00640307180583477, -0.18337848782539368, 0.06681986898183823, -0.08888889849185944, -0.01904493384063244, -0.007426896132528782, -0.08930361270904541, -0.1284722089767456, 0.0361233651638031, 0.07236309349536896, -0.06128595396876335, -0.11682784557342529, 0.17434096336364746, 0.06534247100353241, -1.0756527095776395e-32, 0.02155553176999092, 0.08183978497982025, -0.02068876102566719, -0.029138289391994476, -0.05048229172825813, 0.06170807406306267, 0.1733071655035019, -0.09329266846179962, 0.04254654422402382, -0.2323712855577469, 0.05045512691140175, 0.05506739392876625, -0.05073949694633484, -0.029021531343460083, -0.12820062041282654, 0.03789811208844185, -0.01939646154642105, -0.07288723438978195, -0.04441572725772858, 0.06443903595209122, 0.004431546200066805, 0.2862493097782135, -0.1950596272945404, 0.0032163122668862343, -0.030589036643505096, 0.14480777084827423, 0.020958311855793, -0.02036123350262642, 0.028461772948503494, -0.07301093637943268, -0.010940248146653175, 0.0775982216000557, -0.245792418718338, 0.034364260733127594, -0.03969215601682663, -0.055445343255996704, 0.026613110676407814, -0.15765412151813507, -0.06443403661251068, 0.06905298680067062, 0.06853465735912323, 0.12027646601200104, -0.08321627974510193, 0.024696899577975273, -0.022350454702973366, -0.024789046496152878, 0.08852610737085342, 0.11809734255075455, 0.14041632413864136, -0.025495871901512146, -0.1508978307247162, -0.019587421789765358, 0.036891475319862366, 0.10757062584161758, 0.07007676362991333, -0.08304697275161743, -0.14164385199546814, -0.09576304256916046, 0.05923081561923027, 0.020497402176260948, 0.010172754526138306, 0.12841643393039703, -0.055084340274333954, -0.02143261954188347, 0.07191716134548187, 0.18895426392555237, 0.05381932109594345, -0.04906942695379257, -0.031062854453921318, 0.04649284854531288, -0.0733463317155838, 0.026629682630300522, -0.00842769630253315, -0.1643865704536438, 0.14405518770217896, 0.10616913437843323, -0.047784727066755295, 0.04180889576673508, -0.10690227895975113, 0.021824829280376434, -0.05325727164745331, -0.015224136412143707, -0.048353999853134155, 0.031365688890218735, 0.11362087726593018, 0.03556954860687256, -0.034319210797548294, -0.08566929399967194, 0.0936332494020462, -0.060335855931043625, -0.053082674741744995, -0.07770045101642609, -0.0731808990240097, 0.05239415541291237, -0.0641370639204979, -1.0022603191828239e-07, -0.0031612813472747803, -0.182378351688385, -0.0026494385674595833, -0.15957289934158325, 0.18841958045959473, -0.008009540848433971, -0.13079321384429932, 0.01076750922948122, -0.005821501836180687, 0.2284458577632904, 0.043289028108119965, 0.031686365604400635, -0.08878028392791748, -0.1643444448709488, -0.1781618446111679, 0.14014634490013123, -0.0005499469116330147, -0.0845310240983963, -0.04980837553739548, 0.0860975980758667, -0.22532948851585388, -0.10585527122020721, 0.046286411583423615, 0.02406303398311138, 0.06422974169254303, 0.014073126949369907, 0.06448137760162354, 0.07385706901550293, -0.009466512128710747, -0.02880430407822132, -0.002564438618719578, -0.03814525902271271, 0.06467597186565399, 0.0628126859664917, -0.05896081402897835, -0.0002628667280077934, 0.19886216521263123, 0.1159730777144432, -0.029727857559919357, 0.13142134249210358, 0.10534688830375671, -0.03389553353190422, -0.05373215675354004, 0.029161065816879272, -0.04804205149412155, -0.005592554807662964, -0.17433370649814606, 0.013791453093290329, -0.08543159067630768, -0.2048284113407135, -0.02689945697784424, -0.13992473483085632, 0.034630727022886276, -0.028324997052550316, 0.008617620915174484, 0.11849901080131531, -0.02778933383524418, 0.06569541245698929, -0.010949598625302315, -0.05572623014450073, 0.11027146130800247, 0.0015649390406906605, 0.022998472675681114, -0.06564929336309433], "changes": {"1wk": -3.6993528753252556}}, {"text": "Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform Zacks Equity Research Mon, Jan 27, 2025, 8:36 PM 5 min read In This Article: EXEL -0.81% Shares of Exelixis EXEL were down 5.13% on Jan. 24, following a downgrade in rating by analysts at Oppenheimer. Oppenheimer downgraded EXEL to \u201cPerform\u201d from \u201cOutperform\u201d as the analysts were concerned about the potential differentiation of pipeline candidate zanzalintinib versus cabozantinib following the abstract for STELLAR-001 study at American Society of Clinical Oncology 2025 Gastrointestinal Cancers Symposium (ASCO GI). While Oppenheimer believes data from STELLAR-001 likely derisk the late-stage STELLAR-303 study in metastatic colorectal cancer (CRC), the firm does not necessarily see clear differentiation for zanzalintinib. Hence, it chooses to be on the sidelines for now while awaiting additional clarity. Shares of Exelixis have surged 47.9% in a year against the industry\u2019s decline of 12.4%. Zacks Investment Research Image Source: Zacks Investment Research Exelixis More on EXEL\u2019s STELLAR-303 study On Jan. 25, Exelixis announced results from an expansion cohort of the phase Ib/II STELLAR-001 study evaluating zanzalintinib alone or in combination with Tecentiq (atezolizumab) in patients with previously treated metastatic CRC at the ASCO GI. This cohort of the STELLAR-001 trial included 107 patients randomized equally to receive single-agent zanzalintinib or zanzalintinib in combination with atezolizumab. Patients had unresectable, locally advanced or metastatic RAS wild-type CRC that was non-microsatellite instability-high or non-mismatch repair-deficient. Both progression-free survival and overall survival (OS) were numerically improved by the addition of atezolizumab to zanzalintinib. We note that STELLAR-001 is a global, open-label phase Ib/II study of zanzalintinib as a single agent or in combination with atezolizumab in patients with inoperable locally advanced or metastatic solid tumors. The trial is divided into two parts \u2014 a dose-escalation stage and an expansion cohort stage. The expansion cohorts evaluating zanzalintinib (100 mg) as a single agent or in combination with atezolizumab also include patients with clear cell renal cell carcinoma (RCC), non-clear cell RCC, breast cancer that is hormone receptor-positive and HER-2 negative and castration-resistant prostate cancer. In the overall population arm, the data showed an objective response rate (ORR) of 7.4% for the combination arm and an ORR of 1.9% for zanzalintinib arm. In patients without liver metastasis (NLM), ORR was 18% for the combination arm and 5.9% for the standalone zanzalintinib arm. Oppenheimer cited that the data are overall positive and support the design of phase III STELLAR-303 in metastatic CRC with primary OS analysis in NLM patients. In addition, data from prior trials, including LEAP-017, suggest liver metastases may reduce the benefit of immunotherapy. Story Continues However, per Oppenheimer, the data didn't particularly stand out from prior phase I/II studies of cabozantinib in combination with checkpoint inhibitors in similar settings. Consequently, Oppenheimer is concerned about the differentiations of zanzalintinib and whether it can replace cabozantinib in key indications. EXEL Announces CABINET Study Data at ASCO GI Exelixis announced results from a subgroup analysis of the phase III CABINET pivotal study of patients with extra-pancreatic neuroendocrine tumors (epNET) arising in the gastrointestinal (GI) tract. The analysis showed that cabozantinib was associated with an improvement in progression-free survival compared with placebo in patients with advanced GI neuroendocrine tumors (NET), a subgroup of the epNET cohort. EXEL\u2019s Focus on Cabometyx Label Expansion EXEL\u2019s lead drug, Cabometyx (cabozantinib), is a leading tyrosine kinase inhibitor (\u201cTKI\u201d) for the treatment of RCC. The use of the drug in combination with Bristol Myers\u2019 BMY Opdivo in the first-line setting is boosting sales. BMY\u2019s Opdivo is one of the leading immuno-oncology drugs, and it has been approved for various oncology indications. EXEL is looking to expand Cabometyx. The FDA accepted EXEL\u2019s supplemental new drug application for cabozantinib for patients with previously treated advanced pancreatic neuroendocrine tumors (pNET) and those with previously treated advanced epNET. It assigned a standard review with a target action date of April 3, 2025. The FDA also granted the orphan drug designation to cabozantinib for the treatment of pNET. EXEL is looking to reduce its dependence on Cabometyx with the development of zanzalintinib, a next generation oral TKI. Another study, STELLAR-304, is evaluating zanzalintinib in combination with Opdivo versus sunitinib in previously untreated patients with advanced non-clear cell RCC. Exelixis recently collaborated with pharma giant Merck MRK to evaluate zanzalintinib in combination with its blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) in a late-stage study for treating patients with head and neck squamous cell carcinoma (\u201cHNSCC\u201d). Per the agreement, Merck will supply Keytruda for the ongoing, Exelixis-sponsored phase III STELLAR-305 study in previously untreated PD-L1-positive recurrent or metastatic HNSCC. Data from the phase II portion is expected to be available in the second half of 2025. Exelixis also expects to initiate a late-stage study, STELLAR-311, in the first half of 2025 evaluating zanzalintinib compared with everolimus as a first oral therapy in patients with advanced NET, regardless of the site of origin. Per the collaboration with Merck, two RCC studies are also planned for 2025 and updates on the same will be provided later. EXEL\u2019s Zacks Rank & A Key Pick EXEL currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Immunocore Holdings plc IMCR, which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 90 days, estimates for Immunocore\u2019s 2024 loss per share have narrowed from $1.80 to 94 cents. Loss per share estimates for 2025 have narrowed from $2.33 to $1.66 during the same time frame. IMCR\u2019s earnings beat estimates in two of the trailing four quarters and missed the same in the other two, the average surprise being 25.57%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Exelixis, Inc. (EXEL) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRC", "date": "2025-01-27T17:36:00+00:00", "sentiment": {"score": -0.784384474158287, "confidence": 0.8497269153594971, "probabilities": {"positive": 0.06534244120121002, "negative": 0.8497269153594971, "neutral": 0.08493059873580933}}, "embedding": [-0.0347454771399498, -0.13143734633922577, -0.09409373253583908, 0.013084002770483494, -0.024564187973737717, -0.22154021263122559, -0.030682146549224854, 0.26202836632728577, 0.1163814514875412, -0.013278508558869362, -0.0832236260175705, 0.15118807554244995, 0.1299837827682495, 0.02753080241382122, -0.11690783500671387, 0.037645287811756134, 0.09927501529455185, 0.02330751344561577, -0.08078200370073318, 0.14786915481090546, -0.07160485535860062, -0.07695512473583221, 0.22060994803905487, 0.040862541645765305, -0.04680728539824486, -0.07508618384599686, -0.12444886565208435, 0.13281658291816711, -0.17149069905281067, -0.08706596493721008, 0.11211095750331879, 0.10449960827827454, -0.0015678536146879196, -0.009150121361017227, 0.04256623610854149, -0.015439463779330254, -0.062057990580797195, 0.08688317984342575, -0.14406023919582367, -0.04408307746052742, 0.029303796589374542, -0.02827550657093525, -0.11459306627511978, -0.0474432036280632, -0.051783159375190735, -0.26377931237220764, -0.20581799745559692, -0.061802998185157776, 0.034253641963005066, 0.2903761565685272, -0.19636677205562592, -0.09959416091442108, 0.0012888363562524319, 0.2963373064994812, 0.08938733488321304, 0.014322273433208466, -0.12453771382570267, 0.021311797201633453, 0.040629997849464417, 0.05369888246059418, 0.026114769279956818, -0.10828253626823425, -0.020312577486038208, -0.01992926560342312, 0.11009544134140015, 0.10540493577718735, 0.0036682230420410633, -0.14011026918888092, -0.10066559910774231, 0.006449261214584112, 0.09598196297883987, -0.055123403668403625, 0.01837902143597603, 0.05611851066350937, -0.1805121749639511, 0.08156947791576385, 0.2438506782054901, 0.08342017233371735, -0.049891598522663116, -0.00415029376745224, 0.025646887719631195, 0.10106819868087769, 0.04265621304512024, -0.14513498544692993, -0.03941916301846504, 0.0627884566783905, -0.050820477306842804, 0.16247446835041046, 0.13046282529830933, 0.09517882764339447, 0.12329153716564178, 0.1265106499195099, 0.04268897697329521, -0.024365127086639404, 0.10177312791347504, -0.08062303811311722, -0.07476998120546341, -0.08037649095058441, 0.057194072753190994, -0.00883021205663681, 0.02912304177880287, -0.047202304005622864, -0.024599481374025345, -0.10024887323379517, 0.0017246855422854424, -0.10172213613986969, 0.008822306990623474, 0.02048824541270733, -0.13593916594982147, 0.005455316975712776, 0.02923395484685898, -0.06751696765422821, 0.10142325609922409, 0.0018182187341153622, -0.07141785323619843, 0.24979792535305023, -0.038284655660390854, 0.006996848154813051, 0.05011565238237381, 0.006173097528517246, -0.026195161044597626, 0.07647554576396942, 0.05075665935873985, -0.06418606638908386, 0.1682545393705368, 0.20065806806087494, -0.11404921114444733, 1.4084256094038287e-32, 0.0006043728208169341, -0.017727933824062347, 0.040252089500427246, 0.17464397847652435, -0.018309656530618668, 0.09871852397918701, 0.05503362417221069, 0.02728615701198578, -0.12519340217113495, -0.10846259444952011, -0.053025923669338226, 0.022910185158252716, 0.1713666021823883, 0.06965504586696625, -0.18317103385925293, -0.0668346956372261, 0.014411285519599915, -0.03694240748882294, -0.15291628241539001, 0.03695213049650192, 0.014390970580279827, -0.020868908613920212, -0.035770125687122345, -0.04790841415524483, -0.05598131939768791, 0.15134763717651367, -0.060239214450120926, 0.1672714352607727, -0.010459105484187603, 0.005334238521754742, -0.0739443451166153, 0.014798273332417011, 0.08935137093067169, -0.09115179628133774, -0.048039644956588745, 0.08606525510549545, -0.013582605868577957, -0.031798891723155975, 0.08975885808467865, 0.06604337692260742, -0.04648527503013611, 0.04636242240667343, -0.14724469184875488, -0.0006160023622214794, 0.03839026018977165, -0.19334104657173157, -0.0004036305472254753, -0.020268375054001808, 0.08021759986877441, -0.048661477863788605, 0.02479897439479828, -0.0862109512090683, -0.08252398669719696, -0.04503750801086426, -0.20215466618537903, 0.04796517640352249, -0.16684174537658691, -0.037768371403217316, 0.08882580697536469, 0.02801114320755005, 0.0675322636961937, 0.029186179861426353, -0.03754638135433197, 0.013227693736553192, 0.03430499508976936, 0.09644510596990585, -0.04238542914390564, -0.044358085840940475, -0.13528960943222046, 0.07722051441669464, -0.12882979214191437, -0.013850769028067589, 0.27556556463241577, 0.09314070641994476, 0.1603020280599594, -0.07974573224782944, 0.033559806644916534, 0.04460043087601662, 0.037892237305641174, 0.14981962740421295, -0.1640196144580841, -0.07188813388347626, -0.09017333388328552, 0.16319000720977783, -0.13868339359760284, -0.046175867319107056, -0.03389938548207283, 0.08871077001094818, -0.028730187565088272, -0.012124755419790745, 0.13010399043560028, -0.13677749037742615, -0.1283612847328186, 0.04927387088537216, 0.036568865180015564, -1.4466100740223522e-32, -0.003381301648914814, 0.09671631455421448, 0.02263791672885418, -0.059753190726041794, -0.03751619905233383, 0.07663804292678833, 0.036501139402389526, -0.1148102730512619, 0.012336764484643936, -0.18637216091156006, 0.05409013479948044, 0.2449285089969635, 0.046766798943281174, -0.1765020489692688, -0.09986916184425354, 0.03157659247517586, -0.17269858717918396, -0.005128862336277962, -0.017023850232362747, -0.021693192422389984, 0.0365927591919899, 0.020932726562023163, -0.09511419385671616, 0.0033731572329998016, -0.14273852109909058, 0.1929084062576294, 0.16393248736858368, 0.04527720808982849, -0.0022402536123991013, -0.017261307686567307, -0.03713539242744446, 0.11030159890651703, -0.265277624130249, -0.03815344721078873, 0.023764625191688538, 0.04785408079624176, -0.11364515870809555, -0.17464721202850342, -0.07474519312381744, -0.09015108644962311, -0.0645277202129364, 0.12816230952739716, -0.020892689004540443, -0.07442039996385574, 0.03214650973677635, -0.008123594336211681, 0.14012163877487183, -0.08697783946990967, 0.09296007454395294, -0.047546520829200745, -0.011593064293265343, 0.16817671060562134, -0.03588603809475899, 0.060711223632097244, 0.004274321720004082, -0.015336370095610619, 0.015346622094511986, -0.01362040638923645, -0.14184316992759705, 0.12867334485054016, 0.01516740396618843, 0.20322385430335999, 0.17225125432014465, 0.05676066130399704, 0.08707309514284134, 0.1228618249297142, 0.11639465391635895, -0.022495683282613754, 0.04350806400179863, -0.06315834075212479, -0.03311522305011749, -0.10628056526184082, -0.049099214375019073, -0.10161353647708893, 0.056346409022808075, 0.2303047478199005, -0.07875826954841614, -0.04378044605255127, -0.16323110461235046, 0.01568653993308544, 0.03603814169764519, -0.07345148921012878, -0.04903111606836319, 0.0566452220082283, -0.04130373150110245, 0.11314007639884949, -0.08025220036506653, -0.0110592320561409, 0.0025610309094190598, -0.02559007704257965, -0.09754355251789093, -0.1370207965373993, -0.04917342588305473, -0.015214089304208755, -0.03526618704199791, -1.0099838476662626e-07, 0.02272200956940651, 0.008233093656599522, 0.03601178526878357, -0.023732773959636688, 0.0156254880130291, 0.02761063724756241, -0.06915552914142609, -2.8058886528015137e-05, 0.009409591555595398, 0.14711780846118927, 0.021115314215421677, 0.12997709214687347, -0.08981598913669586, -0.06258079409599304, -0.09868184477090836, 0.009873274713754654, -0.020278440788388252, -0.037928506731987, -0.035269845277071, 0.1900026500225067, -0.17200054228305817, -0.03966519981622696, 0.00846034474670887, -0.12518933415412903, 0.04837169498205185, -0.042375598102808, 0.026793422177433968, 0.1866675317287445, -0.026568245142698288, -0.06902144104242325, -0.02523425966501236, -0.057961102575063705, 0.05515887588262558, -0.006097225472331047, -0.0003751814365386963, -0.014903232455253601, 0.10451368242502213, 0.018166355788707733, -0.010635128244757652, 0.2505365312099457, 0.10392123460769653, -0.014567427337169647, -0.01746373251080513, -0.04670882225036621, -0.16117152571678162, -0.0039658755995333195, -0.1913170963525772, -0.0750449001789093, 0.04734654724597931, -0.06508979201316833, 0.008526043966412544, 0.03676809370517731, -0.15380537509918213, -0.08725979179143906, -0.09673752635717392, 0.03685205429792404, -0.09667104482650757, 0.009355712682008743, -0.012674643658101559, -0.0037772003561258316, 0.026275286450982094, -0.22015929222106934, -0.012835141271352768, 0.006829235702753067], "changes": {"1wk": -5.0107679891274035}}, {"text": "Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA\u00ae (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium Adagene Inc. Mon, Jan 27, 2025, 3:00 PM 5 min read In This Article: ADAG +0.53% Adagene Inc. Muzastotug (ADG126), an Anti-CTLA-4 SAFEbody \u00ae in Combination with pembrolizumab showed 33% overall response rate in microsatellite stable colorectal cancer Four confirmed partial responses out of twelve patients with 20 mg/kg loading dose followed by 10 mg/kg Q3W + pembrolizumab No Grade 4/5 treatment related adverse events were observed and no discontinuations occurred to date SAN DIEGO and SUZHOU, China, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, announced updated clinical data from ADG126 in microsatellite stable colorectal cancer (MSS CRC) at the ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA. \u201cThese data, from the loading dose expansion cohort of our Phase 1b/2 trial, continue to demonstrate ADG126\u2019s potential for patients with colorectal cancer. \u00a0Seeing four confirmed partial responses out of twelve patients, with no treatment related discontinuations, also highlights the differentiated therapeutic index of ADG126. CTLA-4 is clinically validated with a known correlation between dose, efficacy and toxicity to improve outcomes with PD-1 inhibitors, and now we know that our SAFEbody can deliver benefit to patients in a safe and efficacious way,\u201d said Peter Luo, Chairman, CEO & President of R&D at Adagene. Dr. Marwan Fakih, Professor of Medical Oncology and Therapeutics Research at City of Hope added, \u201cMasking technology, which leads to increased intra-tumoral accumulation of cleaved ADG126 and maintains an optimal plasma concentration following higher and repeat dosing of ADG126, as well as enhanced Treg depletion through binding to a novel epitope without Fc engineering, position ADG126 to be a best-in-class CTLA-4 inhibitor.\u201d This Phase 1b/2, open-label, multicenter dose escalation and expansion combination study of ADG126 in combination with Merck\u2019s (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA \u00ae (pembrolizumab; 200 mg, Q3W) in MSS CRC with no liver and peritoneum metastases previously demonstrated efficacy at the 10 mg/kg Q3W dose, with overall response rate (ORR) of 23%, including four confirmed partial responses and one unconfirmed partial response. Newly shared data with the 20 mg/kg loading dose followed by 10 mg/kg Q3W in combination with pembrolizumab achieved an improved ORR of 33%, and all responders remain on treatment at a maintenance dose of 10 mg/kg Q3W or 10 mg/kg Q6W in combination with pembrolizumab. Per protocol, dose modifications were permitted to manage toxicity, enabling investigators to optimize each patient\u2019s course of treatment to further improve the duration of responses. Time to event endpoints will be reported when the data mature in 2025. Due to the enhanced therapeutic index of ADG126 in combination with anti-PD-1, the Company plans to evaluate a broader patient population in the dose expansion cohort, including patients with liver metastases, with standard of care combinations. Story Continues No Grade 4/5 safety events were seen with ADG126 to date and pruritus (25%) was the most commonly observed treatment-related adverse event (TRAE). Higher G2/G3 TRAEs were observed in the loading dose cohort but were managed through dose modification and infrequent use of infliximab/medical intervention, resulting in no discontinuations to date. The totality of data to date supports that Adagene\u2019s anti-CTLA-4, ADG126, plus pembrolizumab has potential to be a best-in-class treatment for patients with MSS CRC. About\u00a0Adagene Adagene Inc.\u00a0(Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene\u00a0combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody \u00ae precision masking technology in multiple approaches at the vanguard of science. Powered by its proprietary\u00a0Dynamic Precision Library\u00a0(DPL) platform, composed of NEObody\u2122, SAFEbody, and POWERbody\u2122 technologies, Adagene\u2019s highly differentiated pipeline features novel immunotherapy programs. The company\u2019s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies in tumor microenvironment, while minimizing on-target off-tumor toxicity in healthy tissues. Adagene\u2019s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multispecific T-cell engagers. For more information, please visit: https://investor.adagene.com . Follow\u00a0Adagene\u00a0on WeChat , LinkedIn and Twitter . SAFEbody \u00ae is a registered trademark in\u00a0the United States, China, Australia, Japan, Singapore, and the European Union. KEYTRUDA \u00ae is a registered trademark of\u00a0Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.,\u00a0Rahway, NJ, USA. Safe Harbor Statement This press release contains forward-looking statements, including statements regarding certain clinical results of ADG126, the potential implications of clinical data for patients, and Adagene\u2019s advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene\u2019s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene\u2019s drug candidates; Adagene\u2019s ability to achieve commercial success for its drug candidates, if approved; Adagene\u2019s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene\u2019s reliance on third parties to conduct drug development, manufacturing and other services; Adagene\u2019s limited operating history and Adagene\u2019s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene\u2019s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene\u2019s clinical development, commercial and other operations, as well as those risks more fully discussed in the \u201cRisk Factors\u201d section in Adagene\u2019s filings with the\u00a0U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to\u00a0Adagene, and\u00a0Adagene\u00a0undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Investor Contact: Bruce Mackle LifeSci Advisors bmackle@lifesciadvisors.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRC", "date": "2025-01-27T12:00:00+00:00", "sentiment": {"score": 0.7491453234106302, "confidence": 0.7596840858459473, "probabilities": {"positive": 0.7596840858459473, "negative": 0.01053876243531704, "neutral": 0.2297772318124771}}, "embedding": [-0.03848857060074806, -0.09756525605916977, -0.017343714833259583, -0.0453406386077404, -0.12314723432064056, -0.17968091368675232, 0.01760539412498474, 0.11023292690515518, 0.11229652166366577, -0.04504283517599106, -0.11409740895032883, 0.07819504290819168, -0.03460168093442917, -0.034749556332826614, -0.011104525066912174, 0.16165918111801147, -0.005466975271701813, 0.06394925713539124, -0.18615958094596863, -0.018985027447342873, 0.03623978793621063, -0.11443546414375305, 0.06286973506212234, 0.09661822021007538, -0.1483384668827057, -0.10134311765432358, -0.036948494613170624, 0.0755811482667923, -0.05842570215463638, -0.08010278642177582, 0.06785103678703308, 0.08267931640148163, 0.06983891129493713, 0.022872038185596466, -0.042245976626873016, -0.05432024225592613, -0.05888396129012108, 0.028643598780035973, -0.14687851071357727, -0.061465173959732056, -0.06647109985351562, 0.04949148744344711, -0.051227156072854996, -0.05193357914686203, 0.058670081198215485, -0.2747570276260376, -0.12025520205497742, -0.03368137776851654, -0.04404769092798233, 0.1973424255847931, -0.032059479504823685, 0.05374724417924881, -0.04748057201504707, 0.19932758808135986, 0.019657911732792854, -0.016154535114765167, -0.08284155279397964, 0.01164206676185131, 0.04611428454518318, -0.025082802399992943, 0.002305448055267334, -0.0972779393196106, -0.028397034853696823, 0.02371695451438427, 0.010146424174308777, 0.05031677335500717, 0.04303068667650223, -0.14858844876289368, -0.09500617533922195, 0.0031429901719093323, -0.0552622489631176, -0.04369387403130531, 0.000788430217653513, 0.13736304640769958, -0.10627017915248871, 0.08272186666727066, 0.18469944596290588, 0.12283667922019958, 0.03624875470995903, -0.0561598464846611, 0.0746372789144516, 0.1116308718919754, 0.043390147387981415, -0.05215483903884888, 0.013009435497224331, 0.05471225082874298, -0.06816749274730682, 0.15322467684745789, 0.05483691766858101, -0.08786476403474808, 0.12967361509799957, 0.06622244417667389, -0.014839202165603638, 0.08386628329753876, 0.05002385377883911, -0.00536531675606966, -0.06069692224264145, -0.1485927700996399, 0.09397055208683014, -0.05514080077409744, -0.0584794357419014, 0.06184988468885422, -0.12543511390686035, -0.07814474403858185, 0.06388447433710098, -0.05977641046047211, -0.019887376576662064, 0.08437396585941315, -0.054626867175102234, 0.012968756258487701, 0.06254246830940247, 0.02456357702612877, 0.09968746453523636, 0.1595926433801651, -0.03270331770181656, 0.17510667443275452, -0.062493421137332916, -0.013561844825744629, 0.19008415937423706, -0.020382363349199295, -0.010536053217947483, -0.018737800419330597, -0.04589695483446121, -0.019753389060497284, 0.13267971575260162, 0.10460597276687622, 0.03043019026517868, 1.3111973859746464e-32, 0.07766605168581009, -0.06111675500869751, 0.11135905981063843, 0.08690977096557617, 0.09379661828279495, -0.038358237594366074, 0.09472021460533142, -0.10852240025997162, -0.14644783735275269, 0.0032873223535716534, -0.01970667950809002, -0.05272584781050682, 0.05671299248933792, 0.18207336962223053, -0.1342426836490631, -3.983639180660248e-05, 0.008597207255661488, 0.0018486583139747381, -0.1504887044429779, -0.04316898435354233, 0.042495571076869965, 0.044201500713825226, -0.03930087387561798, -0.08229490369558334, -0.00897210743278265, 0.21884651482105255, -0.0648026093840599, 0.2112526297569275, 0.03262794017791748, 0.024589739739894867, -0.23029553890228271, -0.004757587797939777, 0.028349237516522408, -0.043952010571956635, -0.1228092759847641, -0.05575064942240715, -0.07907374203205109, -0.07570274919271469, 0.08035111427307129, 0.16333559155464172, 0.11275416612625122, -0.0140007846057415, -0.03311850130558014, -0.004592444282025099, 0.11400626599788666, -0.1507345736026764, -0.07053230702877045, -0.03080476075410843, -0.043219130486249924, 0.15967699885368347, -0.0324753001332283, -0.041366904973983765, 0.002498469315469265, 0.032996319234371185, -0.13268660008907318, -0.03315601497888565, -0.11021790653467178, 0.05795633792877197, 0.10436293482780457, 0.02884794771671295, -0.04096449911594391, 0.007707730866968632, -0.016518855467438698, 0.03691250830888748, -0.025581706315279007, 0.027858980000019073, -0.04395809397101402, -0.03959142789244652, -0.17697244882583618, 0.09808234125375748, 0.013201608322560787, -0.06063621863722801, 0.15867061913013458, 0.10728748142719269, 0.17133691906929016, -0.10470949113368988, 0.09339268505573273, 0.10984116792678833, -0.001345388125628233, 0.08291786164045334, -0.14609500765800476, 0.05380328744649887, -0.07855722308158875, 0.1550256609916687, -0.14603327214717865, -0.1903783082962036, 0.021725337952375412, 0.031206417828798294, -0.1336134970188141, 0.013525737449526787, 0.09626320004463196, -0.02385735884308815, -0.15331920981407166, 0.13368524610996246, 0.0159742534160614, -1.4208451480306477e-32, -0.008817235939204693, 0.12789182364940643, 0.02257792092859745, -0.03502998873591423, -0.09324363619089127, 0.05751396715641022, 0.08571040630340576, -0.07342173904180527, 0.07528440654277802, -0.15609389543533325, 0.054439790546894073, 0.1275540441274643, -0.07108776271343231, -0.07079462707042694, -0.09967153519392014, 0.07353152334690094, 0.03598255291581154, 0.045096613466739655, -0.21595069766044617, 0.11451619118452072, -0.001962948590517044, 0.16683857142925262, -0.05914656072854996, 0.05472700670361519, -0.0909130647778511, 0.014133294112980366, 0.1862221509218216, 0.04064088314771652, 0.012995131313800812, -0.0641610249876976, 0.014603648334741592, 0.10997138917446136, -0.16854871809482574, -0.06745605170726776, -0.0269565861672163, -0.1381411850452423, 0.037297431379556656, -0.1672753095626831, -0.05254072695970535, -0.017150158062577248, -0.0383690781891346, 0.07325947284698486, -0.05611589923501015, -0.004594849422574043, -0.002264668233692646, 0.10505323112010956, 0.19675171375274658, -0.0971086323261261, 0.010276609100401402, 0.057652443647384644, -0.015130728483200073, 0.06545468419790268, 0.06183188781142235, 0.02435215935111046, 0.04621686786413193, -0.041802577674388885, -0.0024623163044452667, -0.11974437534809113, -0.05906949192285538, 0.115559421479702, 0.0006716168718412519, 0.0888872742652893, 0.12176022678613663, 0.015744101256132126, 0.09883151203393936, 0.21601006388664246, 0.04724051058292389, 0.0006002024747431278, 0.023600861430168152, -0.030123673379421234, -0.06507780402898788, -0.08271670341491699, -0.0037783291190862656, -0.08314812183380127, -0.008057873696088791, 0.14759090542793274, -0.12835872173309326, -0.07056225836277008, -0.02388996072113514, -0.04818236455321312, -0.12223228067159653, -0.13346445560455322, -0.07458165287971497, -0.010418741032481194, 0.05665039271116257, 0.12346266210079193, -0.14815247058868408, 0.034505486488342285, 0.007094358094036579, 0.03942780941724777, -0.02478916011750698, -0.13275499641895294, -0.04501620680093765, 0.039580926299095154, -0.03148669749498367, -1.006347360998916e-07, 0.14482662081718445, -0.07200399041175842, -0.08107942342758179, -0.11997510492801666, -0.042378947138786316, 0.0861143246293068, -0.17054340243339539, -0.0032018786296248436, -0.05516853928565979, 0.11548257619142532, 0.05964309722185135, 0.07537759840488434, -0.11175709962844849, 0.032783038914203644, -0.1544543206691742, 0.19479605555534363, -0.010538246482610703, -0.11878368258476257, -0.05572535842657089, 0.04130733013153076, -0.12484371662139893, -0.0018913201056420803, -0.03216184675693512, -0.06557430326938629, 0.17910349369049072, 0.03557934612035751, 0.03106117807328701, 0.1583269238471985, 0.0860782340168953, -0.06096813455224037, 0.011897280812263489, -0.0933692678809166, -0.09170463681221008, 0.1026378870010376, 0.04987505078315735, 0.0776815265417099, 0.10965681076049805, -0.03212667256593704, 0.07531051337718964, 0.17690806090831757, 0.13884148001670837, -0.04911404848098755, 0.0018454763339832425, -0.07196678221225739, -0.07374857366085052, 0.08380550146102905, -0.14631196856498718, -0.06843070685863495, -0.003553125075995922, -0.07196047902107239, -0.07696089148521423, -0.10198961943387985, -0.07605313509702682, -0.07999718189239502, -0.1092064380645752, 0.025162454694509506, -0.11190168559551239, -0.020210839807987213, 0.19251558184623718, -0.033875204622745514, -0.03435203433036804, -0.10465328395366669, -0.02273987978696823, 0.014992296695709229], "changes": {"1wk": -3.6993528753252556}}]